- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01751594
Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men
28 de julio de 2017 actualizado por: University of North Carolina, Chapel Hill
The proposed research study aims to conduct a culturally-based secondary prevention intervention targeted toward HIV-positive Black young men who have sex with men (B-YMSM) to explore (1) feasibility and acceptability (Trial 1 and Trial 2) and (2) evidence of potential efficacy (Trial 2).
The primary outcomes will be health promotion behaviors (i.e., treatment adherence, sexual risk reduction, reduction in substance use behaviors, and HIV status disclosure).
Psychosocial factors (i.e.
self-esteem, critical consciousness, and socio-political awareness) will be examined as secondary outcomes.
Descripción general del estudio
Estado
Terminado
Intervención / Tratamiento
Descripción detallada
First, the protocol team will finalize the development and manualization of Health 4 Life (H4L) a comparison intervention, which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention.
H4L will be a health promotion and life skills intervention to account for time and attention.
Following this the protocol team will then implement Trial 1.
In this trial, the intervention specialist and a "peer buddy" (intervention co-facilitator) from one AMTU will conduct one wave of both MOVE and H4L.
The team will then conduct an analysis of the process data and revise the two interventions (MOVE and H4L).
Upon revising the interventions, the protocol team will implement Trial 2. In this trial, the protocol co-chairs and the interventionist from Trial 1 will train interventionists and peer buddies from four new AMTUs; these interventionists and peer buddies will run the revised MOVE and H4L interventions.
Each site will be designated as either a treatment or comparison site, and they will conduct two waves of their assigned intervention.
The team at that time will conduct data analyses and then modify and manualize the final version of MOVE and H4L.
Tipo de estudio
Intervencionista
Inscripción (Actual)
92
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90027
- Children's Hospital of Los Angeles
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- Stroger Hospital and the CORE Center
-
-
New York
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
Tennessee
-
Memphis, Tennessee, Estados Unidos, 38105
- St. Jude Children's Research Hospital
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine - Texas Children's Hospital
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
16 años a 24 años (Niño, Adulto)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Masculino
Descripción
To be considered eligible for enrollment into Trial 1 and Trial 2, an individual must meet the criteria listed below:
- Receives services at one of the selected AMTU sites or one of their community partners;
- Biological male at birth and self identifies as male gender at the time of consent;
- Self identifies as "Black" (including Black/African-American, Black Latino, Black/Afro-Caribbean, Black/African immigrant, or any self-identified member of the African Diaspora);
- HIV-infected as documented by medical record review or verification with referring medical professional;
- Between the ages of 16-24 years, inclusive, at the time of consent;
- HIV-infected through sexual behavior;
- At least one sexual encounter involving oral or anal sex with a male partner in the past year;
- Ability to understand both written and spoken English;
- Willingness to participate in a group-based intervention with other HIV-positive B-YMSM and agree to respect the privacy of other group members;
- Willingness and ability to attend the first group session on any of the date chosen by the site staff and;
- Willingness to provide signed informed consent or assent with parental/legal guardian permission as applicable.
To be considered eligible for enrollment, an individual must not meet any of the criteria listed below.
- Active psychiatric condition that in the opinion of the site personnel would interfere with the ability to give true informed consent and to adhere to the study requirements;
- Visibly distraught and/or visibly emotionally unstable (i.e., exhibiting suicidal, homicidal, or violent behavior);
- Active drug or alcohol use or dependence that, in the opinion of the site personnel, would interfere with the ability to give true informed consent and to adhere to the study requirements;
- Acute illness that, in the opinion of the treating clinician, would interfere with the participant's ability to adhere to the protocol requirements and/or interfere with the protocol objectives.
- Previous participation in ATN 090, "Development of a Secondary Prevention Intervention Targeting HIV-Positive Black Young Men Who have Sex with Men." (NOTE: YAB members from ATN090 cannot participate in ATN 104)
- Previous participation in Trial 1 of ATN104 and;
- Current enrollment in any other behavioral intervention study or program. Any cases that are uncertain require Protocol Team approval.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: H4L Comparison Intervention
|
Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention.
H4L will be a health promotion and life skills intervention to account for time and attention.
|
|
Experimental: MOVE Intervention
|
MOVE involves four sessions.
Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length).
They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle.
Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Finalize and manualize a critical consciousness based intervention for HIV positive B-YMSM
Periodo de tiempo: 2 years
|
To finalize and manualize Mobilizing Our Voices for Empowerment (MOVE) resulting in an intervention with evidence of potential efficacy in reducing sexual risk and substance use behaviors and promoting treatment adherence and HIV status disclosure, as well as self-esteem, critical consciousness, and socio-political awareness.
At the same time a non-critical consciousness intervention Health 4 Life (H4L) which will be used as comparison will also be finalized and manualized.
H4L is primarily a health promotion and life skills intervention for HIV-positive B-YMSM.
|
2 years
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Silla de estudio: Gary Harper, PhD, DePaul University
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Enlaces Útiles
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de abril de 2012
Finalización primaria (Actual)
1 de junio de 2014
Finalización del estudio (Actual)
1 de junio de 2014
Fechas de registro del estudio
Enviado por primera vez
14 de diciembre de 2012
Primero enviado que cumplió con los criterios de control de calidad
14 de diciembre de 2012
Publicado por primera vez (Estimar)
18 de diciembre de 2012
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
1 de agosto de 2017
Última actualización enviada que cumplió con los criterios de control de calidad
28 de julio de 2017
Última verificación
1 de marzo de 2016
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
- Seropositividad al VIH
Otros números de identificación del estudio
- ATN 104
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .